Code intelligence

FDA-BLA761530 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-BLA761530.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: LUMVOA (VELIGROTUG-VVZE) — Type 1 - New Molecular Entity

Policy FDA-BLA761530 · Ophthalmology

Critical

LUMVOA (veligrotug) was approved on June 26, 2026 as a new molecular entity administered intravenously, placing it squarely in the Part B billing pathway as a provider-administered injectable. As a br

View alert